New high-throughput screening technologies to improve cannabinoid production in yeast.
Award amount
$224,928Program and phase
SBIR · Phase IAward year
2019Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- LUCERNA INC
- Proposal award date
- 2018-12-01
- Contract end date
- 2020-11-30
- UEI
- J3MWGA6WFCG3
- Solicitation number
- PA18-574
- Topic code
- NCCIH
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- In vivo imaging platform for DM1 drug discovery
- Targeted RNA degradation assay for new antiviral drug discovery
- Cell-based RNA degradation assay for C9ALS/FTD drug discovery
- Fluorescent IRE sensor for synucleinopathy drug discovery
- Cell-based assay directly monitoring RNA Polymerase I activity for cancer drug discovery
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Using scalable ultrasonic nano-emulsification to improve pharmacokinetic properties of the natural product curcumin.
- Botanical Drug for Chemotherapy Induced Nausea and Vomiting
- Leveraging Large Scale Bioinformatics and AI for Natural Product Drug Discovery and Target Selection
- Member Engagement Application for Personalized Arts-Based Social Prescriptions
- Evaluation of a novel soil-derived Mycobacterium as a nutritional supplement to promote stress resilience
Research funding history
22 SBIR/STTR records share this UEI (2011–2025). Reported award amounts total $10,266,039. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, National Science Foundation